CCND1
ENSG00000110092
Target class
Other cytosolic protein
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Other names
- U21B31
- Target name
- CCND1
- Gene name
- Cyclin D1
- Gene symbol
- CCND1
- Protein name
- G1/S-specific cyclin-D1 (B-cell lymphoma 1 protein) (BCL-1) (BCL-1 oncogene) (PRAD1 oncogene)
- BCL1
- D11S287E
- PRAD1
- Gene biotype
- Protein coding
- Gene family
- Cyclins
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 202
- Tissue specificity (Gini)
- 0.48
- Tissue specificity (tau)
- 0.837
- KEGG gene identifiers
- hsa:595
- Protein interaction confidence
- 0.833133
- Protein interaction partners
- 173
- R-HSA-187577
- R-HSA-1912408
- R-HSA-3214858
- R-HSA-6785807
- R-HSA-69231
- R-HSA-75815
- R-HSA-8849470
- R-HSA-8853884
- R-HSA-8878166
- R-HSA-8934593
- R-HSA-8951430
- R-HSA-8951936
- R-HSA-9018519
- R-HSA-9634638
- R-HSA-9661069
- R-HSA-9754119
- R-HSA-9825892
- R-HSA-9929491
- End position
- 69654474
- Start position
- 69641143
- Chromosome
- 11
- Strand
- Forward
- Nucleus . Cytoplasm . Nucleus membrane . Note=Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members. .
- Nucleoplasm
- PubMed 20399237
- PubMed 29279382
- PubMed 40307251
- PubMed 9106657
- Tissue specificity (tau)
- 0.837173
- Expression inequality (Gini)
- 0.479934
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 202
- Skin - Not Sun Exposed (Suprapubic)
- 110.9
- Skin - Sun Exposed (Lower leg)
- 102.19
- Esophagus - Mucosa
- 96.55
- Nerve - Tibial
- 94.81
Expression in transcripts per million
- Cells - Cultured fibroblasts202
- Skin - Not Sun Exposed (Suprapubic)110.9
- Skin - Sun Exposed (Lower leg)102.19
- Esophagus - Mucosa96.55
- Nerve - Tibial94.81
- Artery - Aorta87.22
- Vagina71.69
- Prostate71.53
- Artery - Tibial70.17
- Artery - Coronary64.45
- Lung62.14
- Adipose - Subcutaneous59.56
- Breast - Mammary Tissue56
- Thyroid50.63
- Minor Salivary Gland44.5
- Esophagus - Muscularis41.26
- Pituitary40.99
- Esophagus - Gastroesophageal Junction33.37
- Kidney - Medulla30.3
- Bladder30.28
- Adipose - Visceral (Omentum)28.02
- Adrenal Gland27.44
- Heart - Atrial Appendage27.38
- Colon - Sigmoid26.71
- Liver25.71
And 29 more, listed on the interactive page.
- GO:0000082
- GO:0000122
- GO:0006974
- GO:0009410
- GO:0010971
- GO:0031571
- GO:0044321
- GO:0070141
- GO:0000307
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0017053
- GO:0031965
- GO:0003714
- GO:0005515
- GO:0019899
- GO:0019901
- GO:0042826
- GO:0043539
- GO:0061575
- GO:0070064
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_CCND1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.
- cell-based: LTEA_HepaRG_CCND1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (364)
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
- A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
- A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
Drugs (2)
- Briciclib G1/S-specific cyclin D1 inhibitor
- Palbociclib CDK6/cyclin D1 inhibitor